Agios Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 386
- Market Cap
- $2.6B
- Website
- http://www.agios.com
- Introduction
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: Tebapivat Matched Placebo
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06924970
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: [13C2,15N3]-tebapivat
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06745271
- Locations
- 🇺🇸
Taha El-Shahat, Madison, Wisconsin, United States
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06648824
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06286046
Single and Multiple Ascending Dose Study and Food Effect Study for AG181
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06286033
- Locations
- 🇺🇸
ICON 1255 East 3900 South, Salt Lake City, Utah, United States
A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT05777993
- Locations
- 🇨🇦
McMaster Centre for Transfusion Medicine McMaster University, Hamilton, Ontario, Canada
🇯🇵Toho University - Omori Medical Center, Ota-Ku, Japan
🇯🇵Tohoku University Hospital, Sendai, Miyagi, Japan
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05610657
- Locations
- 🇺🇸
Orlando Clinical Research Center (OCRC), Orlando, Florida, United States
🇺🇸Orange County Research Center (OCRC), Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami (CPMI), Miami, Florida, United States
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05490446
- Locations
- 🇫🇷
Hôpital Saint Louis, Paris, France
🇪🇸C.H. Regional Reina Sofia - PPDS, Cordoba, Spain
🇪🇸Hospital Universitario La Paz - PPDS, Madrid, Spain
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
- Conditions
- Pediatric Pyruvate Kinase DeficiencyPediatric Hemolytic Anemia
- Interventions
- Drug: Mitapivat-matching placebo
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05175105
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Healthcare of Atlanta - Emory, Atlanta, Georgia, United States
🇺🇸Stanford Medicine, Palo Alto, California, United States
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension Period
- Conditions
- Pediatric Hemolytic AnemiaPediatric Pyruvate Kinase Deficiency
- Interventions
- Drug: Mitapivat-matching placebo
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT05144256
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇹🇷Ege University Faculty of Medicine, Izmir, Adana, Turkey
🇺🇸Weill Cornell Medical College, New York, New York, United States